101.58
+0.33%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Themis Medicare
Its shares trade on NSE under the ticker THEMISMED.NS. It has been listed since 2 April 2007. In the fiscal year to 31 March 2026, it reported revenue of ₹3.42bn and net income of ₹11.4m. At that date it held total assets of ₹5.98bn and shareholders' equity of ₹3.99bn.
Themis Medicare Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-04-02. Themis Medicare Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The firm operates through one segment: Pharmaceuticals. The firm manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Apr 2007
- Employees
- 996
- Website
- themismedicare.com ↗
Leadership
Pay as last reported
- Dr. Dinesh PatelExecutive Chairman of the Board, since 2022₹12.9m
- Dr. Sachin PatelChief Executive Officer, Managing Director, Executive Director, since 2017₹12.6m
- Mr. Tushar DalalChief Financial Officer
- Mr. Pradeep ChandanCompliance Officer, Company Secretary
- Shri. Rajneesh AnandNon-Executive Independent Director₹160,000
- Mr. Bhasker IyerNon-Executive Independent Director₹160,000
- Mr. Nikunt RavalAdditional Non-Executive Independent Director
- Ms. Manjul SandhuNon-Executive Independent Director₹160,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Themis Medicare Ltd manufactures therapeutic pharma products in India with 996 employees.
- Themis Medicare Ltd offers analgesic and anti-inflammatory products like Aquadol Tpm Gel and Etojet 90 10'S.
- Themis Medicare Ltd operates in the Pharmaceuticals segment with subsidiaries in UK and India.
Weaknesses
- Themis Medicare Ltd has no subsidiaries in the United States or Europe beyond Carpo Medical Limited (UK).
- Themis Medicare Ltd's product range is limited to India's domestic market.
- Themis Medicare Ltd's business is concentrated in the Pharmaceuticals sector with no diversification.
Opportunities
- Themis Medicare Ltd can expand its analgesic product line to include new formulations in India.
- Themis Medicare Ltd can leverage its API activity to enter international markets.
- Themis Medicare Ltd can grow through acquisitions in the Indian pharmaceutical sector.
Threats
- Themis Medicare Ltd faces competition from other Indian pharmaceutical companies in the domestic market.
- Themis Medicare Ltd must comply with strict Indian pharmaceutical regulations.
- Themis Medicare Ltd's reliance on India's domestic market exposes it to economic fluctuations in India.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.